Celgene Corp (NASDAQ:CELG)

CAPS Rating: 5 out of 5

A biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases.

Results 1 - 20 of 237 : 1 2 3 4 5 6 7 8 9 10 Next »

Recs

1
Member Avatar afketter (81.97) Submitted: 5/7/2014 10:05:17 PM : Outperform Start Price: $72.49 CELG Score: +13.94

Celgene has been brought down due to the whole biotech sector dropping, but they have solid earnings and are cheap on a 2016 basis. Not all of biotech will recover, but CELG will be one that moves a lot higher in the next 2 years

Recs

0
Member Avatar TerryFool (< 20) Submitted: 4/21/2014 8:05:51 AM : Outperform Start Price: $69.58 CELG Score: +19.14

INVEST BUY@ 140 TP 193 CAPS 4

Recs

1
Member Avatar awallejr (83.78) Submitted: 4/10/2014 5:18:40 PM : Outperform Start Price: $68.46 CELG Score: +17.78

Might be a little early but oversold.

Recs

0
Member Avatar ShoreDoc (60.87) Submitted: 4/9/2014 4:12:55 PM : Outperform Start Price: $73.86 CELG Score: +11.40

pipeline, valuation

Recs

0
Member Avatar DrGoldin (99.71) Submitted: 3/29/2014 2:25:12 AM : Outperform Start Price: $57.33 CELG Score: +26.61

The annihilation of Celgene continues, and a few years down the road people are going to wonder what on earth investors were thinking in March of 2014. Sitting tight with this one.

Recs

0
Member Avatar jbond009 (39.82) Submitted: 3/25/2014 8:24:38 PM : Outperform Start Price: $72.86 CELG Score: +12.96

Extremely oversold, very low P/E ratio

Recs

0
Member Avatar Chemdawg (72.06) Submitted: 3/7/2014 2:09:37 AM : Outperform Start Price: $79.06 CELG Score: +4.67

lots of old people in this country ...plus obama care

Recs

0
Member Avatar SmartAce (99.85) Submitted: 2/18/2014 3:10:25 PM : Outperform Start Price: $80.72 CELG Score: -1.55

I can't begin to explain that. Or the craziness inside myself and everyone else.
Pat

Recs

0
Member Avatar herodotous (< 20) Submitted: 2/4/2014 1:59:44 AM : Outperform Start Price: $74.54 CELG Score: +2.97

Excellent pipeline and prospects for continued growth.

Recs

0
Member Avatar klarcbarr (30.98) Submitted: 1/15/2014 5:25:47 AM : Outperform Start Price: $83.90 CELG Score: -4.37

The company inspires overall confidence through process and innovation. The blazing track record and robust pipeline forces me to conclude this one is a no-brainer.

Recs

0
Member Avatar gypsystem (40.08) Submitted: 1/11/2014 12:47:38 AM : Outperform Start Price: $85.24 CELG Score: -6.22

Great pipeline

Recs

0
Member Avatar ruinas (49.34) Submitted: 1/9/2014 8:02:51 PM : Underperform Start Price: $84.38 CELG Score: +5.04

time to relax a bit, and reinvent itself

Recs

0
Member Avatar 401ktimer1 (57.18) Submitted: 1/6/2014 4:35:47 PM : Outperform Start Price: $82.47 CELG Score: -3.18

IBD 50

Recs

0
Member Avatar Flygal5 (98.97) Submitted: 12/6/2013 11:23:41 AM : Outperform Start Price: $82.69 CELG Score: -5.00

new effective medications for cancers

Recs

0
Member Avatar 1stPrincipleFool (22.32) Submitted: 11/20/2013 6:51:14 PM : Outperform Start Price: $78.09 CELG Score: +0.23

growind demand

Recs

0
Member Avatar megamill (< 20) Submitted: 10/30/2013 9:12:24 PM : Outperform Start Price: $75.89 CELG Score: +1.66

Great list of drugs in the pipe line, along with their specialty areas.

Recs

0
Member Avatar pa1vette (51.28) Submitted: 10/25/2013 4:25:40 PM : Outperform Start Price: $78.00 CELG Score: -1.58

celg

Recs

0
Member Avatar 2trpop (93.57) Submitted: 10/18/2013 2:57:59 PM : Outperform Start Price: $79.99 CELG Score: -5.39

fstg experiment

Recs

0
Member Avatar HealthyMoney (< 20) Submitted: 10/15/2013 6:16:22 PM : Outperform Start Price: $78.03 CELG Score: -5.04

Revlimid label expansion will supply the underlying revenue base. Apremilast approval could help Celgene carve some market share in the huge anti-inflammatory market dominated by injectable blockbusters.

Recs

0
Member Avatar MakeMoney2013 (24.18) Submitted: 10/8/2013 7:38:47 AM : Outperform Start Price: $77.24 CELG Score: -6.20

going with a cramer hunch

Featured Broker Partners


Advertisement